CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary

Reka Varnai, C. Sipeky, Lajos Nagy, Sandor Balogh, Bela Melegh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2–3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to examine their effect in patients with higher AC requirements. Most impact on dose reduction is accountable for CYP2C9*2/*3 (59%) and for VKORC1*2/*2 (45.5%), and on dose increase for newly evaluated VKORC1*3/*4 (22.5%) diplotypes. VKORC1*3 and *4 alleles seem to balance the dose-reducing effect of VKORC1*2 allele. Being a carrier of combination of VKORC1*2 and CYP2C9*2,*3 polymorphisms, rather than of one of these SNPs, is associated with higher risk of over-anticoagulation (up to 34.3%) in long-term AC treatment. The pharmacogenetic dosing algorithm involving VKORC1, CYP2C9 diplotypes and age explains 30.4% of AC dosing variability (p < 6.10 × 10−9). Correlation between the studied diplotypes and bleeding events could not be revealed.

Original languageEnglish
Pages (from-to)282-289
Number of pages8
JournalEnvironmental Toxicology and Pharmacology
Volume56
DOIs
Publication statusPublished - Dec 1 2017

Keywords

  • Acenocoumarol
  • Bleeding event
  • CYP2C9
  • Dose
  • Hungary
  • VKORC1

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary'. Together they form a unique fingerprint.

  • Cite this